Jeff Davies

Dr Davies brings over 35 years of biopharmaceutical industry experience, including senior executive roles at CSL. His positions at CSL included Executive Vice President & General Manager, Asia Pacific, where he had full P&L responsibility across pharmaceuticals, plasma, vaccines, and diagnostics in Australia, New Zealand, China, and the Asia Pacific region. Dr Davies was part of CSLs due diligence teams, which led to the acquisitions of the plasma fractionation businesses of Swiss Red Cross (2000) and Aventis Behring (2003), thus transforming CSL into the global company, CSL Behring. As Global Head of Plasma Product R&D at CSL Behring.Dr Davies is a founding director of the Centre for Biopharmaceutical Excellence, a pharmaceutical consulting firm, and Pure Solutions, a specialist provider of sterile fill-finish and microbiological testing services. Dr Davies has held numerous advisory and board roles, including with the Pharmaceutical Industry Council, Australian Red Cross, and Medicines Australia.